IL-10 (human):Fc (human) (rec.) (non-lytic)
|Synonyms||Interleukin-10; Cytokine Sythesis Inhibitory Factor; CSIF|
The extracellular domain of human IL-10 (aa 19-178) is fused to the N-terminus of the Fc region of a mutant human IgG1.
Shows the biological function of the IL-10 moiety and exerts a prolonged circulating half-life caused by the modified Fc domain.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
Reconstitute 10µg vial in 100µl sterile water.
Reconstitute 50µg vial in 50µl sterile water.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Interleukin-10 (IL-10) is a cytokine produced by activated Th2 cells, B cells, keratinocytes and monocytes/macrophages. In vitro murine and human IL-10 inhibits cytokine synthesis by Th1 cells, natural killer cells and monocytes/macrophages. Several studies have suggested the potential application of IL-10 as an anti-inflammatory agent in the treatment of septic shock and as an immunosuppressive agent in certain T cell mediated autoimmune diseases.
- Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation: X.X. Zheng, et al.; J. Immunol. 154, 5590 (1995)